Oncology Venture A/S management team
Steve is CEO and a Director of Oncology Venture A/S since September 2019. He brings more than 30 years of commercial industry experience focused in oncology from several leading multinational pharmaceutical biotech companies. Steve has served in CEO positions in both privately owned and Nasdaq listed biotech-companies, all with a late stage oncology focus in which he has led financing, commercialization and re-structuring activities.
He was previously President & Chief Executive Officer of Apexian Pharmaceuticals, an early stage oncology discovery and development company focused in novel targets to treat cancer, and earlier served as Chief Executive Officer of Raphael Pharmaceuticals (formerly Cornerstone Pharmaceuticals), an oncology company focused in cancer metabolism.
Earlier in his career, Steve served as the Senior Vice President and President, Commercial Operations (North America) for Mallinckrodt Pharmaceuticals leading the company listing on NYSE. In addition, he previously held senior leadership positions at General Electric, Johnson & Johnson, Eli Lilly & Company and Bristol Myers Squibb. In addition to his executive experience, Steve currently serves on the Board of Directors of Sunesis Pharmaceuticals and Bionumerik Pharmaceuticals. He previously served on the Board of Directors for Apexian Pharmaceuticals, Cornerstone Pharmaceuticals and PCAsso Diagnostics, LLC, and was Co-Chair of the BioNJ Personalized Medicine & Diagnostics Committee Council (CMOC), the Ontario Institute of Cancer Research Commercial Committee (OICR) and the Pharmaceutical Industry Board of the American Pediatric Family Foundation.
Steve received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University. Steve is a member of the Board of Directors of Sunesis Pharmaceuticals and BioNumerik Pharmaceuticals.
Number of warrants: 3 523 875.
Chief Financial Officer
Henrik brings more than 30 years of experience in CFO and Senior Vice President roles within the life sciences and health care sectors, and joined our executive team in 2019. He has been with Oncology Venture since October 2019.
The primary focus in his career has been in venture financing, including IPOs as well as follow on capital increases in the public markets, investor relations, finance, project management, and strategic development.
Henrik has formerly served in such senior roles with companies like Scandinavian Micro Biodevices ApS, Astion Pharma A/S, NeuroSearch A/S, Novo A/S, and Ferrosan A/S. He has also a broad financial and managerial experience from several listed and unlisted companies as member of their Boards of Directors.
Henrik holds a Masters Degree in international economics and strategic management from Copenhagen Business School, Denmark. Henrik is a member of the Board of Directors of Initiator Pharma A/S and Hartmanns A/S.
Number of warrants: 2 114 324.
Other Management Members
Chief Scientific Officer
Steen is the founder of Oncology Venture A/S and the inventor of DRP™, the Drug Response Prediction Platform which is Oncology Venture’s core technology and science platform. Knudsen is a Professor of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. Steen Knudsen founded Oncology Venture in 2004.
Number of shares: 6 168 680.
Number of warrants: 0.
Chief Medical Officer
Marie brings thirty years of experience in the pharmaceutical and biotechnology industries to our senior management team, and has a strong track record leading successful clinical development of therapeutics, including regulatory and medical affairs.
She leads clinical development of our current precision medicine oncology pipeline, including our lead assets 2X-121, Dovitinib, and LiPlaCis™.
She previously led the successful development and regulatory approval of more than 10 novel drug products in the U.S. and U.K., within oncology, endocrinology and cardiology. Marie has fluency in regulatory interactions with the FDA and EMEA, including INDs, NDAs, IDEs (for predictive biomarkers and/or companion diagnostics), and product issues.
She also manages interactions with the oncology key opinion leaders that sit on our Scientific Advisory Board.
She holds both Medical Doctorate (M.D.) and Doctorate of Science (Dr.Sc.) degrees, and is a member of the American College of Physicians (ACP), American Medical Association (AMA). American Society of Clinical Oncology, and the American College of Obstetricians and Gynecologists (ACOG).
James G. Cullem
Senior Vice President, Corporate Development
James is an experienced biotechnology executive, and has been part of our senior team since 2014.
He brings 20+ years of diverse experience in life sciences organizational management, business development & licensing, intellectual property & technology transfer/commercialization, partnership creation/management, and strategic planning as a member of executive teams.
During his tenure with Oncology Venture, James has been responsible for the identification and acquisition of most of our lead clinical oncology assets, including big pharma therapeutics Dovitinib (from Novartis) and 2X-121 (from Eisai). He has also spearheaded our potential reverse merger discussions, as well as clinical program out-licensing, partnership, and joint venture discussions, both in the U.S. and in major foreign oncology markets.
James has previously designed and negotiated a broad span of life science deals, has founded and lead several early-stage biotech companies, and is a catalyst for businesses taking the next step in the fields of precision medicine and predictive/companion diagnostics, novel drug targets, proteomics and genomics, and clinical-stage cancer therapeutic development.
He holds a B.S. degree in Biochemistry, a juris doctorate (J.D.) degree specializing in patent & I.P. law, and has registered patent attorney status.
Chief Technology Officer
Thomas Jensen is pioneering the bridging of: good science, effective laboratory techniques and bioinformatics to advance the biology of cancer. He founded & leads Oncology Venture’s laboratories in Denmark and in the USA. Along side nurturing our global laboratories, he is instrumental in building our investor relations, securing operational financing and fostering business growth of Oncology Venture.
Amongst Thomas’ accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing.This allows for high resolution analysis of cancer patients’ biopsies. His inventions are an important foundation of the DRP® -Drug Response Prediction platform. Thomas Jensen co-founded Oncology Venture in 2004.
Number of shares: 713 620.
Number of warrants: 916 040.